Routine board and committee reshuffling with no operational or strategic catalysts. No trading implications, monitor upcoming pipeline updates or financial filings for material events.
CMMB drugs
CMMB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $1.72entry
- T+1 · 6mo ago +4.65%α +4.25% · $1.80
- T+5 · 5mo ago +1.74%α +5.56% · $1.75
- T+20 · 5mo ago +31.98%α +32.98% · $2.27
- T+60 · 3mo ago +58.14%α +55.64% · $2.72
Price Chart
How similar events traded
Executive Summary
Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance committee, replacing Claude Nicaise and Jill Quigley who resigned without disagreement. The board also shuffled audit committee members. These are routine governance changes with no material financial or strategic impact.
Key Facts
- Gwen Melincoff appointed as Class I Director and chair of nominating and governance committee, effective June 1, 2026
- Claude Nicaise resigned as director and audit committee member on May 29, 2026
- Jill Quigley resigned as director and audit committee member on May 29, 2026
- Neither resignation was due to any disagreement with the company
- Neil Cohen and Nissim Darvish appointed to audit committee on June 1, 2026
- Neil Cohen resigned as nominating committee chair, replaced by Gwen Melincoff
- Board size set at five directors
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No identified risks from this filing, routine governance changes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003058 |
| Document: 0001178913-26-003058-index-headers.html | 0001178913-26-003058 |
| Document: 0001178913-26-003058-index.html | 0001178913-26-003058 |
| Document: 0001178913-26-003058.txt | 0001178913-26-003058 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers